PLSE
Next earnings: Aug 11, 2026
Signal
Leaning Bearish11!1
Price
1
Move-9.41%Selling pressure
Volume
1
Volume1.8× avgHeavy volume
Technical
1
RSIRSI 79Overbought
PRICE
Prev Close
27.10
Open
26.15
Day Range23.74 – 26.80
23.74
26.80
52W Range12.56 – 27.98
12.56
27.98
78% of range
VOLUME & SIZE
Avg Volume
322.2K
FUNDAMENTALS
P/E Ratio
-22.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.38
Market-like
Performance
1D
-9.41%
5D
+27.47%
1M
+19.70%
3M
+3.72%
6M
+70.49%
YTD
+78.81%
1Y
+42.82%
Best: YTD (+78.81%)Worst: 1D (-9.41%)
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin -91% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 7.3 · FCF negative
Neutral
Key MetricsTTM
Market Cap$1.70B
Revenue TTM$751.0K
Net Income TTM-$74.57M
Free Cash Flow-$55.50M
Gross Margin-91.1%
Net Margin-9929.0%
Operating Margin-10392.1%
Return on Equity-86.7%
Return on Assets-91.4%
Debt / Equity0.11
Current Ratio7.26
EPS TTM$-1.10
Alpha SignalsFull Analysis →
What Moves This Stock

FDA regulatory milestone announcements (510(k) clearance decisions, IDE approvals for pivotal trials)

Clinical trial data readouts showing efficacy/safety for dermatology or oncology indications

Strategic partnership announcements with established medical device distributors or pharmaceutical companies

Intellectual property developments (patent grants, litigation outcomes affecting NPS technology exclusivity)

Macro Sensitivity
Economic Cycle

moderate - As a pre-revenue company, near-term stock performance is insulated from economic cycles and driven by binary clinical/regulatory events. Post-commercialization, dermatology/aesthetic procedures are elective and discretionary, making demand moderately sensitive to consumer confidence and disposable income. Medical aesthetics spending correlates with wealth effects and employment stability, with 20-30% demand variability during recessions. Oncology applications would be less cyclical due to medical necessity.

Interest Rates

High sensitivity through multiple channels: (1) Valuation compression as rising rates increase discount rates applied to distant future cash flows, disproportionately impacting pre-revenue growth stocks trading on 2028+ earnings potential. (2) Financing costs for future debt raises, though current 10.02x current ratio and 0.09 debt/equity suggest minimal near-term debt dependency. (3) Competitive cost of capital for target customers (dermatology practices) financing equipment purchases, potentially slowing adoption. 100bp rate increase historically compresses pre-revenue medtech valuations by 15-25%.

Key Risks

FDA regulatory rejection or delayed approval pathway requiring additional clinical trials, extending time-to-market by 18-36 months and exhausting cash reserves before revenue generation

Reimbursement uncertainty as payers may classify NPS procedures as cosmetic/experimental, limiting adoption to cash-pay markets and capping addressable market at 30-40% of initial projections

Technology obsolescence risk if competing energy modalities (plasma, focused ultrasound) demonstrate superior outcomes or safety profiles before Pulse achieves market penetration

Investor Profile

growth/speculative - Attracts biotech-focused growth investors and venture capital crossover funds seeking asymmetric returns from successful FDA approval and commercialization. High-risk, high-reward profile with binary outcomes. Recent 74% three-month return and 51% six-month return indicate momentum-driven trading and speculation around regulatory catalysts. Not suitable for value or income investors given negative cash flows, no dividends, and unproven business model. Institutional ownership likely concentrated among healthcare specialist funds with high risk tolerance.

Watch on Earnings
FDA 510(k) clearance decision dates and any additional information requests extending review timelinesClinical trial patient enrollment rates and data readout timing for pivotal dermatology studiesQuarterly cash burn rate and ending cash balance relative to projected commercialization timelinePatent issuance and freedom-to-operate opinions protecting core NPS technology from competitive entry
Health Radar
3 strong3 concern
49/100
Liquidity
7.26Strong
Leverage
0.11Strong
Coverage
0.0xConcern
ROE
-86.7%Concern
ROIC
-106.3%Concern
Cash
$81MStrong
ANALYST COVERAGE4 analysts
BUY
+22.2%upside to target
Buy
250%
Hold
250%
2 Buy (50%)2 Hold (50%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 5 signals bullish
9/10
Technicals
RSI RangeRSI 79 — Overbought, caution
~
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 7.26 — healthy liquidity
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentSep 10, 2026
In 116 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 19.7%

+55.1% vs SMA 50 · +85.8% vs SMA 200

Momentum

RSI78.9
Overbought — pullback risk
MACD+2.56
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$27.98+14.0%
Current
$24.55
EMA 50
$17.35-29.3%
EMA 200
$13.35-45.6%
52W Low
$12.56-48.8%
52-Week RangeNear 52-week high
$12.5678th %ile$27.98
Squeeze SetupVolume-based
Moderate Squeeze Setup

Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.

20-Day Money Flow
Acc days:2
Dist days:2
Edge:Even
Volume Context
Avg Vol (50D)305K
Recent Vol (5D)
717K+135%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 2 analysts
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$150000
$131151$168800
-$1.02
±16%
Low1
FY2026(current)
$3.1M
$2.7M$3.6M
+2000.0%-$1.10
±16%
Low2
FY2027
$12.5M
$11.0M$14.0M
+296.8%-$1.15
±16%
Low2
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryPLSE
Last 8Q
+17.1%avg beat
Beat 7 of 8 quartersMissed 1 Estimates falling
+42%
Q2'24
+17%
Q3'24
+33%
Q4'24
+29%
Q1'25
-8%
Q3'25
+6%
Q4'25
+2%
Q1'26
+16%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
4 Buys/2 SellsNet Buying
NET BUYERS$26.6M bought · $0 sold · 30d window
Duggan Robert WDir
$13.0M
May 11
BUY
Laviolette Paul ACEO
$295K
May 11
BUY
Laviolette Paul ACEO
$295K
May 11
BUY
Duggan Robert WDir
$13.0M
May 11
BUY
Danahy Kevin PatrickChief Commerci…
$118K
Feb 18
SELL
Danahy Kevin PatrickChief Commerci…
$467K
Feb 12
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
BlackRock, Inc.
1.3M
2
Portolan Capital Management, LLC
733K
3
GEODE CAPITAL MANAGEMENT, LLC
492K
4
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
463K
5
STATE STREET CORP
457K
6
BALYASNY ASSET MANAGEMENT L.P.
265K
7
GRIFFIN ASSET MANAGEMENT, INC.
225K
8
LMR Partners LLP
213K
News & Activity

PLSE News

About

pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and

Industry
Surgical and Medical Instrument Manufacturing
David DanitzSenior Vice President of Engineering
Edison ManuelVice President of Operations
Paul Arthur LaViolettePresident, Chief Executive Officer & Co-Chairman of the Board
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
PLSE
$24.55-9.41%$1.7B-2079457.1%1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.96%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-3.98%50.3+398824.8%-300567.2%1500